bluuebunny/crossref_metadata_2025 huggingface dataset:
sup 4 from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental Figure 4. A) qPCR analysis of miR-21-5p expression level after 4 treatments with TPN-21 in PDO 286. B) Relative tumor burden after (4 I.V injection of PBS (n=6) TPN-control n=6 or TPN-21 n=5 (5mg/kg). For qPCR each miRNA sample was normalized on the basis of its 18s content.
Supplementary Figure S2 from Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Authors: Hui Edwin P. , Ma Brigette B. Y. , Loong Herbert H. F. , Mo Frankie , Li Leung , King Ann D. , Wang Ki , Ahuja Anil T. , Chan Charles M. L. , Hui Connie W. C. , Wong Chi H. , Chan Anthony T. C.
Published: April 2023

Pharmacokinetic profile of axitinib.
Supplemental legend from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental legend
Sup. Figure 6: TRK-A with G595R mutation caused steric hindrance to foretinib. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

The coordinates of TRK-A for the docking study of foretinib and entrectinib were prepared from the X-ray structures as stated in the Materials and Methods section. The coordinate of the G595R mutant for the docking study of foretinib was prepared using the Discovery Studio (version 4.5, BIOVIA, San Diego, CA, USA). The three-dimensional conformations of compounds were generated by OMEGA (version 3.141592-1.23.2.3, OpenEye Scientific Software, Santa Fe, NM, USA) with default settings. Docking was performed using FRED (version 3.0.1, OpenEye Scientific Software) with constraints making a hydrogen bond with Met592. The displayed docking models had the best FRED score.
Supplemental Figure 1 from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
Authors: Jain Preetesh , Keating Michael J. , Wierda William G. , Sivina Mariela , Thompson Philip A. , Ferrajoli Alessandra , Estrov Zeev , Kantarjian Hagop , O'Brien Susan , Burger Jan A.
Published: April 2023

Survival outcomes for patients with del17p (n=21) treated with ibrutinibrituximab (IR) - Complex vs Non-Complex karyotype.
Supplementary Figure 6 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

Characterization of CCR1+ cells in the tumor microenvironment of CRC liver metastases. Simultaneous immunofluorescence staining for CCR1 (red) and MPO (A), CD11b (B), CD33 (C), HLA-DR (D), CD15 (E), CD16 (F), ARG1 (G) or MMP9 (H) (green).
Movie S5 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2)-CR cells treated with the control.
Supplementary Figure 3 from Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis
Authors: Yamamoto Takamasa , Kawada Kenji , Itatani Yoshiro , Inamoto Susumu , Okamura Ryosuke , Iwamoto Masayoshi , Miyamoto Ei , Chen-Yoshikawa Toyofumi F. , Hirai Hideyo , Hasegawa Suguru , Date Hiroshi , Taketo Makoto M. , Sakai Yoshiharu
Published: April 2023

A) Kaplan-Meier curves of OS in CRC patients after pulmonary resection. B) Effects of CCL15 expression on OS in CRC patients after pulmonary resection with lung metastases.
Supplementary Legend from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Legend for Supplementary Figures, Table and Files
Supplementary Figure 4 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Figure 4 displays Copy number alterations and allele frequencies across all chromosomes for SMNs.
Supplemental Figure 1 from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Sensitivity analysis comparing mutation prevalence estimates by site of biopsy of tissue used for next generation sequencing panel in metastatic colorectal cancer.
Supplementary Table 1 from Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma
Authors: Chicard Mathieu , Colmet-Daage Leo , Clement Nathalie , Danzon Adrien , Bohec Mylène , Bernard Virginie , Baulande Sylvain , Bellini Angela , Deveau Paul , Pierron Gaëlle , Lapouble Eve , Janoueix-Lerosey Isabelle , Peuchmaur Michel , Corradini Nadège , Defachelles Anne Sophie , Valteau-Couanet Dominique , Michon Jean , Combaret Valérie , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Detailed Clinical and Sequencing Data of all Cases.
Supplementary Table 3 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Authors: Nieuweboer Annemieke J.M. , de Graan Anne-Joy M. , Hamberg Paul , Bins Sander , van Soest Robert J. , van Alphen Robbert J. , Bergman Andries M. , Beeker Aart , van Halteren Henk , ten Tije Albert J. , Zuetenhorst Hanneke , van der Meer Nelly , Chitu Dana , de Wit Ronald , Mathijssen Ron H.J.
Published: April 2023

Reasons for patients going off-protocol
Supplemental Figure 1 from Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor
Authors: Vitiello Gerardo A. , Medina Benjamin D. , Zeng Shan , Bowler Timothy G. , Zhang Jennifer Q. , Loo Jennifer K. , Param Nesteene J. , Liu Mengyuan , Moral Alec J. , Zhao Julia N. , Rossi Ferdinand , Antonescu Cristina R. , Balachandran Vinod P. , Cross Justin R. , DeMatteo Ronald P.
Published: April 2023

ROS production in 2 week imatinib-treated and vehicle-treated KitV558del/+ murine CD45+ immune cells
Table S2 from PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity
Authors: Buchan Sarah L. , Fallatah Mohannad , Thirdborough Stephen M. , Taraban Vadim Y. , Rogel Anne , Thomas Lawrence J. , Penfold Christine A. , He Li-Zhen , Curran Michael A. , Keler Tibor , Al-Shamkhani Aymen
Published: April 2023

List of genes in clusters 3 and 4 with the greatest fold-changes between monotherapy and combination therapy groups
Table S1 from Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
Authors: Chen Xin , Chen Zhenyao , Yu Shanxun , Nie Fengqi , Yan Shuai , Ma Pei , Chen Qinnan , Wei Chenchen , Fu Hangjiang , Xu Tianwei , Ren Shengnan , Sun Ming , Wang Zhaoxia
Published: April 2023

Patients clinical information
Figure S3 from Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
Authors: Chen Xin , Chen Zhenyao , Yu Shanxun , Nie Fengqi , Yan Shuai , Ma Pei , Chen Qinnan , Wei Chenchen , Fu Hangjiang , Xu Tianwei , Ren Shengnan , Sun Ming , Wang Zhaoxia
Published: April 2023

CBFB is a target of miR-204-5P, and CBFB expression in GC
Figure S6 from Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Schunselaar Laurel M. , Quispel-Janssen Josine M.M.F. , Kim Yongsoo , Alifrangis Constantine , Zwart Wilbert , Baas Paul , Neefjes Jacques
Published: April 2023

Fig. S6. Stability assessment of differential gene expression analysis. (A) Heat map indicating P-values with leave one out cross-validation experiment. Columns are held out samples and rows are held-out genes. (B) Ranks of DEGs in terms of P-values in the held-out experiment. (C) Consensus clustering of samples with DEGs obtained from each of the held-out experiment. Color bar indicate patient group.
Supplementary Figure S2 from Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
Authors: Chan Nancy , Willis Amy , Kornhauser Naomi , Ward Maureen M. , Lee Sharrell B. , Nackos Eleni , Seo Bo Ri , Chuang Ellen , Cigler Tessa , Moore Anne , Donovan Diana , Vallee Cobham Marta , Fitzpatrick Veronica , Schneider Sarah , Wiener Alysia , Guillaume-Abraham Jessica , Aljom Elnaz , Zelkowitz Richard , Warren J. David , Lane Maureen E. , Fischbach Claudia , Mittal Vivek , Vahdat Linda
Published: April 2023

This figure shows that the amount of time to achieve first Cp {less than or equal to} 17 mg/dL was significantly reduced for TN compared to non-TN patients.
Suppl. Figure 2 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

Surface PD-L1 present on exosomes
Supplementary Figure S4 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S4: In vivo activity of CIK cells against allogeneic mCSCs
Figure S3 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

Bland-Altman plot of endoxifen (in µg/l) at 3 months and at 6 months.
Figure S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

Flowchart of patients who were included/excluded from the study.
Supplementary Figure S1 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S1: Transduction and vector insertion control of melanoma cells
Supplementary Tables from Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy
Authors: Mancarella Caterina , Pasello Michela , Ventura Selena , Grilli Andrea , Calzolari Linda , Toracchio Lisa , Lollini Pier-Luigi , Donati Davide Maria , Picci Piero , Ferrari Stefano , Scotlandi Katia
Published: April 2023

Supplementary Tables include Supplementary Table S1, S2, S3, S4, S5, and S6
Supplementary Table 4 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

Baseline characteristics of the validation cohort.
Supplementary Figure S3 from Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Krumbholz Manuela , Hellberg Julia , Steif Benedikt , Bäuerle Tobias , Gillmann Clarissa , Fritscher Torsten , Agaimy Abbas , Frey Benjamin , Juengert Joerg , Wardelmann Eva , Hartmann Wolfgang , Juergens Heribert , Dirksen Uta , Metzler Markus
Published: April 2023

ctDNA levels calculated by normalization of the EWSR1-FLI1 signal to the signal of the single copy gene albumin compared to normalization with the plasma volume used for DNA extraction. Plasma sample quality was monitored by reference gene (albumin) per volume.
Supplementary Figure S2 from Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Krumbholz Manuela , Hellberg Julia , Steif Benedikt , Bäuerle Tobias , Gillmann Clarissa , Fritscher Torsten , Agaimy Abbas , Frey Benjamin , Juengert Joerg , Wardelmann Eva , Hartmann Wolfgang , Juergens Heribert , Dirksen Uta , Metzler Markus
Published: April 2023

Individual genomic EWSR1-FLI1 or EWSR1-ERG fusion sequences. Repeat regions are highlighted in gray.
Supplementary Figure 1 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Authors: Wang Dongsheng , Qian Guoqing , Zhang Hongzheng , Magliocca Kelly R. , Nannapaneni Sreenivas , Amin A.R.M. Ruhul , Rossi Michael , Patel Mihir , El-Deiry Mark , Wadsworth J. Trad , Chen Zhengjia , Khuri Fadlo R. , Shin Dong M. , Saba Nabil F. , Chen Zhuo G.
Published: April 2023

Co-IP of HER2 in MDA686TU cells
Figure S6 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 6. (A & B) OCI-AML3 cells were transduced with CTRL shRNA, PKCÎµ shRNA_1 or PKCÎµ shRNA_2 and 24 hours later cells from each condition were treated with 100ÂµM NAC (A) or 50ÂµM glutathione (B), every 12 hours until the end of the experiment. Four days after treatment, cells from each condition were assessed for Annexin V staining by flow cytometry (****p<0.0001). OCI-AML3 cells were also treated with 20 ÂµM Menadione with and without NAC of glutathione as a positive control for anti-oxidant activity. Data are represented as mean {plus minus} SD of three technical replicates. (C) Mouse MLL-AF9 leukemia cells were transduced with CTRL shRNA or PkcÎµ shRNA. Forty-eight hours after transduction, cells were treated with 25ï�­M BHA or DMSO. Forty-eight hours after BHA treatment, cells from each condition were assessed for Annexin V staining by flow cytometry (*p{less than or equal to}0.05). Data are represented as mean {plus minus} SD of three technical replicates. (D) OCI-AML3 cells stably transduced with retroviruses co-expressing SOD2-IRES-Catalase (SOD2-Catalase) and GFP or control vector (CTRL) were transduced with CTRL shRNA, PKCÎµ shRNA_1 or PKCÎµ shRNA_2. Four days after transduction, cells were analyzed for mitochondrial superoxides production. Data are represented as mean {plus minus} SD of three independent experiments for each panel. (*p{less than or equal to}0.05;**p{less than or equal to}0.01).
Supplementary Materials and Methods from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

Cell lines, Reagents and sequence information for primers and probes.
Figure S4 from Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Authors: Gavvovidis Ioannis , Leisegang Matthias , Willimsky Gerald , Miller Natalie , Nghiem Paul , Blankenstein Thomas
Published: April 2023

MHC-I expression in re-isolated MC703-KLL tumor cells
Supplementary fig 5 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
Authors: Piulats Josep M. , Vidal August , García-Rodríguez Francisco J. , Muñoz Clara , Nadal Marga , Moutinho Catia , Martínez-Iniesta María , Mora Josefina , Figueras Agnés , Guinó Elisabet , Padullés Laura , Aytés Àlvaro , Molleví David G. , Puertas Sara , Martínez-Fernández Carmen , Castillo Wilmar , Juliachs Merce , Moreno Victor , Muñoz Purificación , Stefanovic Milica , Pujana Miguel A. , Condom Enric , Esteller Manel , Germà Josep R. , Capella Gabriel , Farré Lourdes , Morales Albert , Viñals Francesc , García-del-Muro Xavier , Cerón Julián , Villanueva Alberto
Published: April 2023

Impact of some RNAi clones on cisplatin toxicity in Caenorhabditis elegans adults
Supplementary Table 2 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Authors: McCoach Caroline E. , Le Anh T. , Gowan Katherine , Jones Kenneth , Schubert Laura , Doak Andrea , Estrada-Bernal Adriana , Davies Kurtis D. , Merrick Daniel T. , Bunn Paul A. , Purcell W. Tom , Dziadziuszko Rafal , Varella-Garcia Marileila , Aisner Dara L. , Camidge D. Ross , Doebele Robert C.
Published: April 2023

Read depths for ALK and ROS1 used in NGS
Figure S2 from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplemental Figure 2. Effect of combination of NY-ESO-1 vaccine and decitabine treatment on NY-ESO-1 expression.
Phosphorylation of IRAK4 is present in early-passage patient-derived cell lines and independent pancreatic tissue microarray from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Zhang Daoxiang , Li Lin , Jiang Hongmei , Knolhoff Brett L. , Lockhart Albert C. , Wang-Gillam Andrea , DeNardo David G. , Ruzinova Marianna B. , Lim Kian-Huat
Published: April 2023

Supplementary Figure 1. Phosphorylation of IRAK4 is present in early-passage patient-derived cell lines and independent pancreatic tissue microarray.
Supplementary Figure S5 from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

RNAscope on sections from cutaneous metastasis
Detailed description of materials, method; and supplementary figure legends from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Zhang Daoxiang , Li Lin , Jiang Hongmei , Knolhoff Brett L. , Lockhart Albert C. , Wang-Gillam Andrea , DeNardo David G. , Ruzinova Marianna B. , Lim Kian-Huat
Published: April 2023

Detailed description of materials, method; and supplementary figure legends
Movie S2 from HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging
Authors: Martins Carlos D. , Da Pieve Chiara , Burley Thomas A. , Smith Rhodri , Ciobota Daniela M. , Allott Louis , Harrington Kevin J. , Oyen Wim J.G. , Smith Graham , Kramer-Marek Gabriela
Published: April 2023

Representative 3D-rendering of segmented control and AUY922-treated MCF-7 xenografts following PET/CT image acquisition 3 h after 89Zr-DFO-ZHER3:8698 injection on days 0 and 14.
Supplementary Tables 1-5, Supplementary Figures 1-6 from Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α
Authors: Lowery Caitlin D. , Blosser Wayne , Dowless Michele , Knoche Shelby , Stephens Jennifer , Li Huiling , Surguladze David , Loizos Nick , Luffer-Atlas Debra , Oakley Gerard J. , Guo Qianxu , Iyer Seema , Rubin Brian P. , Stancato Louis
Published: April 2023

Table S1: Detailed cell line information; Table S2: Reagent details; Table S3: p values from proliferation assays presented in Supplemental Fig. 3 and Supplemental Fig. 4; Table S4: Tumor volume summary for pediatric rhabdoid tumor and osteosarcoma xenografts; Table S5: Characterization of patient-derived xenograft models for PDGF receptor and ligand expression; Figure S1. PDGF receptor expression in pediatric bone and soft tissue tumors cell lines; Figure S2. Olaratumab blocks PDGFRα activation in normal human fibroblasts; Figure 3. The AT/RT cell lines BT-12 and BT-16 are negative for PDGF receptor expression and are not affected by olaratumab treatment; Figure 4. Olaratumab reduces PDGFRα-expressing tumor cell proliferation alone and in combination with chemotherapy; Figure 5: Supplemental Figure 5. Olaratumab serum concentration is consistent across different mouse models of pediatric bone and soft tissue sarcoma; Figure 6. Characterization of CCSARC005 osteosarcoma patient-derived xenograft model for PDGFRα expression; Figure 5. Olaratumab serum concentration is consistent across different mouse models of pediatric bone and soft tissue sarcoma; Figure 6. Characterization of CCSARC005 osteosarcoma patient-derived xenograft model for PDGFRα expression.
Figure S3 from The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma
Authors: Wang Zheng , Hao Yajing , Zhang Chuanbao , Wang Zhiliang , Liu Xing , Li Guanzhang , Sun Lihua , Liang Jingshan , Luo Jianjun , Zhou Dabiao , Chen Runsheng , Jiang Tao
Published: April 2023

Biological Process in high virus infection group (A) and low virus infection group (B)
Supplementary Tables from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Supplementary Tables S1-S4
Supplemenaty Tables from Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Authors: Ye Zhenqing , Dong Haidong , Li Ying , Ma Tao , Huang Haojie , Leong Hon Sing , Eckel-Passow Jeanette , Kocher Jean-Pierre A. , Liang Han , Wang Liguo
Published: April 2023

Table S1-S8
Supplementary Figures 1-7 from Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Authors: Tan Yee Sun , Sansanaphongpricha Kanokwan , Xie Yuying , Donnelly Christopher R. , Luo Xiaobo , Heath Blake R. , Zhao Xinyi , Bellile Emily , Hu Hongxiang , Chen Hongwei , Polverini Peter J. , Chen Qianming , Young Simon , Carey Thomas E. , Nör Jacques E. , Ferris Robert L. , Wolf Gregory T. , Sun Duxin , Lei Yu L.
Published: April 2023

Figure S1. Generation of HLA-A*02-restricted EGFR-specific CD8+ cytotoxic T lymphocytes; Figure S2. SOX2 inhibits IFN-I signaling by promoting autophagy-mediated degradation of STING; Figure S3. Validation of C57BL/6-syngeneic mouse squamous cell carcinoma cells; Figure S4. Characterization of MOC2-E6/E7 tumors; Figure S5: Clinical and immunological correlations of SOX2 expression in human HNSCC; Figure S6. SatVax (Q19D; Q15L) effectively controls tumor growth in larger established tumors and improves survival; Figure S7. Treatment schedule and individual tumor growth curves of Sox2-positive tumors
Supplementary Information from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

File containing Supplementary Materials and Methods, references for Supplementary Materials and Methods, and Supplementary Figure legends.
Supplementary Figure 3 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Supplementary Figure S3. MUC4 expression and outcome of patients with luminal breast cancer respect. Kaplan-Meier analysis of the probability of DFS of patients with luminal breast cancer (HER2-negative, estrogen receptor-positive), based on the expression of MUC4. The clinicopathological characteristics of this cohort are shown in Supplementary Table S1.
Supplementary Figure 2 from TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
Authors: Mercogliano María F. , De Martino Mara , Venturutti Leandro , Rivas Martín A. , Proietti Cecilia J. , Inurrigarro Gloria , Frahm Isabel , Allemand Daniel H. , Deza Ernesto Gil , Ares Sandra , Gercovich Felipe G. , Guzmán Pablo , Roa Juan C. , Elizalde Patricia V. , Schillaci Roxana
Published: April 2023

Supplementary Figure S2. Determination and scoring of MUC4 and TNFα expression in breast cancer biopsies by IHC. A, tissue microarrays were used to establish a score of MUC4 by IHC analysis as described by Workman et al (17). Score 0 represents no stain to less than 30% of cells stained faintly, 1+ greater than 30% of cells stained with light to moderate intensity, 2+ greater than 50% of cells stained moderately, 3+ intense staining of majority of the epithelial population. The yellow arrow in the inset of MUC4 (score 0) shows positive staining in endothelial cells, used as an internal control. B, TNFα score was equivalent to that described for MUC4. For both proteins scores of 2+ and 3+ were considered as positive expression.
Suppl. Figure 1 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

Graphical representation of IFN-ð�›¾ ELISpots using peripheral blood mononuclear T cells, co-cultivated with dendritic cells, pulsed with autologous tumor lysate fractions of (A) the first (1st) PF2D dimension and corresponding (B) second (2nd) PF2D dimension of patients NCH1390, NCH612, and NCH519a. Solid line represents mean background of negative control (PBL). F: fraction, PBL: peripheral blood lymphocytes (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Table S1 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Authors: Dong Xiao-Feng , Liu Tian-Qi , Zhi Xu-Ting , Zou Jie , Zhong Jing-Tao , Li Tao , Mo Xiang-Lan , Zhou Wei , Guo Wen-Wen , Liu Xia , Chen Yuan-Yuan , Li Meng-Yang , Zhong Xiao-Gang , Han Ya-Min , Wang Zhong-Hao , Dong Zhao-Ru
Published: April 2023

Table S1: The primers of target genes detected by qRT-PCR
Supplementary Data from Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer
Authors: Belur Nagaraj Anil , Kovalenko Olga , Avelar Rita , Joseph Peronne , Brown Annalyn , Surti Arshia , Mantilla Sandra , DiFeo Analisa
Published: April 2023

Supplementary Figure S1. Generation of acquired cisplatin resistant models in EOC. Supplementary Figure S2. Expression of mitotic marker p-H3-Ser-10 in response to mitotic arrest and release in cisplatin sensitive and resistant cells. Supplementary Figure S3. Si-PLK1 phenotype in OV231 and OV231-CP30 Supplementary Figure S4. Generation of acquired resistance models of Volasertib in EOC. Supplementary Figure S5. Phospho-Ser-133 CyclinB1 expression in Cisplatin/Volasertib sensitive/resistant cells. Supplementary Figure S6. Effect of Volasertib on cell viability in Sh-PLK1 OV81.2- CP40 cells.
Figure S1-4 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Authors: Dong Xiao-Feng , Liu Tian-Qi , Zhi Xu-Ting , Zou Jie , Zhong Jing-Tao , Li Tao , Mo Xiang-Lan , Zhou Wei , Guo Wen-Wen , Liu Xia , Chen Yuan-Yuan , Li Meng-Yang , Zhong Xiao-Gang , Han Ya-Min , Wang Zhong-Hao , Dong Zhao-Ru
Published: April 2023

Figure S1 JASPAR bioinformatics software was used to analyse the human VEGF and Cyclin D1 promoter region. Figure S2. The COX-2/PGE2 axis regulates HIF-2α levels through a p-VHLmediated degradation pathway under hypoxic conditions. Figure S3 COX-2-specific inhibitors synergistically enhance the anti-tumour activity of sorafenib treatment Figure S4. The COX-2/PGE2 axis regulates HIF-2α activity to promote hepatocellular carcinoma development and reduce the sensitivity of sorafenib treatment.
Table S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Table S2
Figure S6 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental Figure S6: In vivo expression of IGF-1R and ErbB3 in HPAF-II tumors over time.
Supplementary Data from Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice
Authors: Duperret Elizabeth K. , Trautz Aspen , Ammons Dylan , Perales-Puchalt Alfredo , Wise Megan C. , Yan Jian , Reed Charles , Weiner David B.
Published: April 2023

Supplementary Figure 1: Construct design and expression. Supplementary Figure 2: Comparison of Native and SynCon FAP vaccines in C57Bl/6 mice. Supplementary Figure 3: Comparison of Native and SynCon FAP vaccines in Balb/c mice. Supplementary Figure 4: Efficacy of FAP vaccine in therapeutic prostate and breast tumor models. Supplementary Figure 5: Alteration of the tumor microenvironment using hyaluronidase is less effective at synergizing with DNA vaccines. Supplementary Figure 6: Immune responses from mice receiving combination mTERT + FAP vaccination. Supplementary Figure 7: Impact of SynCon FAP vaccine on immune cell subsets by flow cytometry. Supplementary Figure 8: FAP expression and immune cell infiltration in patients.
Figure S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental Figure S2: Istiratumab inhibits growth factor-induced AKT phosphorylation across a pancreatic cancer cell line panel.
Table S4 from 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Maytin Edward V. , Anand Sanjay , Riha Margo , Lohser Sara , Tellez Alejandra , Ishak Rim , Karpinski Lauren , Sot Janine , Hu Bo , Denisyuk Anton , Davis Scott C. , Kyei Angela , Vidimos Allison
Published: April 2023

Side effects of topical 5FU and PDT in the study patients
Supplementary Table from Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study
Authors: Zembutsu Hitoshi , Nakamura Seigo , Akashi-Tanaka Sadako , Kuwayama Takashi , Watanabe Chie , Takamaru Tomoko , Takei Hiroyuki , Ishikawa Takashi , Miyahara Kana , Matsumoto Hiroshi , Hasegawa Yoshie , Kutomi Goro , Shima Hiroaki , Satomi Fukino , Okazaki Minoru , Zaha Hisamitsu , Onomura Mai , Matsukata Ayami , Sagara Yasuaki , Baba Shinichi , Yamada Akimitsu , Shimada Kazuhiro , Shimizu Daisuke , Tsugawa Koichiro , Shimo Arata , Tan Ern Yu , Hartman Mikael , Chan Ching-Wan , Lee Soo Chin , Nakamura Yusuke
Published: April 2023

Supplementary Table S1 Association between all CYP2D6 genotype and ER status in pre-treatment tissue.
Supplementary File S2 from Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Gupta Santosh , Li Jing , Kemeny Gabor , Bitting Rhonda L. , Beaver Joshua , Somarelli Jason A. , Ware Kathryn E. , Gregory Simon , Armstrong Andrew J.
Published: April 2023

File S2: List of non-redundant copy number-altered genes from > 50% (more than 4 of 7) of cases from AR copy neutral (wild type) for IPA.
Table S4 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study
Authors: Moeung Sotheara , Chevreau Christine , Broutin Sophie , Guitton Jérôme , Lelièvre Bénédicte , Ciccolini Joseph , Massart Christophe , Fléchon Aude , Delva Rémy , Gravis Gwenaëlle , Lotz Jean-Pierre , Bay Jacques-Olivier , Gross-Goupil Marine , Paci Angelo , Marsili Sabrina , Malard Laurence , Chatelut Etienne , Thomas Fabienne
Published: April 2023

Parameter estimates obtained from the population pharmacokinetic model evaluating inter-occasion (inter-day and inter-cycle) variability.
Table S2 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study
Authors: Moeung Sotheara , Chevreau Christine , Broutin Sophie , Guitton Jérôme , Lelièvre Bénédicte , Ciccolini Joseph , Massart Christophe , Fléchon Aude , Delva Rémy , Gravis Gwenaëlle , Lotz Jean-Pierre , Bay Jacques-Olivier , Gross-Goupil Marine , Paci Angelo , Marsili Sabrina , Malard Laurence , Chatelut Etienne , Thomas Fabienne
Published: April 2023

Full and reduced covariate equations obtained from the model-building dataset (n = 58 patients)
Supplementary Tables S1 and S2 from Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers
Authors: Shigeyasu Kunitoshi , Toden Shusuke , Zumwalt Timothy J. , Okugawa Yoshinaga , Goel Ajay
Published: April 2023

Supplementary Tables S1 and S2
supplemental legend from Exosomes in Human Breast Milk Promote EMT
Authors: Qin Wenyi , Tsukasaki Yoshikazu , Dasgupta Santanu , Mukhopadhyay Nitai , Ikebe Mitsuo , Sauter Edward R.
Published: April 2023

supplemental legend
Supplementary Data File 3 from Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Authors: Pietrasz Daniel , Pécuchet Nicolas , Garlan Fanny , Didelot Audrey , Dubreuil Olivier , Doat Solène , Imbert-Bismut Francoise , Karoui Mehdi , Vaillant Jean-Christophe , Taly Valérie , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

Survival probability according to KRAS mutation in detected ctDNA.
Supplementary Tables from Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Authors: Singer Christian F. , Tan Yen Y. , Fitzal Florian , Steger Guenther G. , Egle Daniel , Reiner Angelika , Rudas Margaretha , Moinfar Farid , Gruber Christine , Petru Edgar , Bartsch Rupert , Tendl Kristina A. , Fuchs David , Seifert Michael , Exner Ruth , Balic Marija , Bago-Horvath Zsuzsanna , Filipits Martin , Gnant Michael
Published: April 2023

Supplemental Table 1. ypT0+ypN0 vs. HER2 ratios Supplemental Table 2. ypT0is+ypN0 vs. HER2 ratios Supplemental Table 3. ypT0is vs. HER2 ratios
Supplement Figure 1 from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Authors: McKay Rana R. , Werner Lillian , Mostaghel Elahe A. , Lis Rosina , Voznesensky Olga , Zhang Zhenwei , Marck Brett T. , Matsumoto Alvin M. , Domachevsky Liran , Zukotynski Katherine A. , Bhasin Manoj , Bubley Glenn J. , Montgomery Bruce , Kantoff Philip W. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Black and white figure for supplement.
Supplement - Clean version from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Authors: McKay Rana R. , Werner Lillian , Mostaghel Elahe A. , Lis Rosina , Voznesensky Olga , Zhang Zhenwei , Marck Brett T. , Matsumoto Alvin M. , Domachevsky Liran , Zukotynski Katherine A. , Bhasin Manoj , Bubley Glenn J. , Montgomery Bruce , Kantoff Philip W. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Clean version of supplement for submission.
Supplemental Tables and figures legends from Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Authors: Hulbert Alicia , Jusue-Torres Ignacio , Stark Alejandro , Chen Chen , Rodgers Kristen , Lee Beverly , Griffin Candace , Yang Andrew , Huang Peng , Wrangle John , Belinsky Steven A. , Wang Tza-Huei , Yang Stephen C. , Baylin Stephen B. , Brock Malcolm V. , Herman James G.
Published: April 2023

Supplemental Tables and figures legends
CONSORT from A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Sayyid Rashid K. , Evans Andrew , Hersey Karen , Maloni Ranjena , Hurtado-Coll Antonio , Kulkarni Girish , Finelli Antonio , Zlotta Alexandre R. , Hamilton Robert , Gleave Martin , Fleshner Neil E.
Published: April 2023

CONSORT
Supplementary Table S3 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Pearson correlation between the levels of CDA transcripts and the cytotoxicity of a panel of drugs.
Supplementary Table S1 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Comparison of CDA mRNA expression data between cancerous and non-cancerous tissues.
Suppl. Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Suppl. Tables
Figure S5 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

RGD mAbs do not affect tubule formation or vascular permeability
Supplemental Figure 3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

(A) Western blot confirming the knockdown of SMAD4 levels by stable expression of short-hairpin RNA in SCC25 cell line. (SC: scrambled control shRNA, SMAD4KD: shRNA against SMAD4). (B) Matrigel colony formation assay was performed for SCC25 cell line (controls and SMAD4 knock-downs) treated with PBS, 100nM or 1000nM cetuximab. (C) Western blot showing MAPK and JNK activity in SMAD4-depleted or control SCC25 cells.
supplemental legend from Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response
Authors: Kickingereder Philipp , Götz Michael , Muschelli John , Wick Antje , Neuberger Ulf , Shinohara Russell T. , Sill Martin , Nowosielski Martha , Schlemmer Heinz-Peter , Radbruch Alexander , Wick Wolfgang , Bendszus Martin , Maier-Hein Klaus H. , Bonekamp David
Published: April 2023

supplemental legend
Supplemental Material (for publication) File #1 from Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response
Authors: Kickingereder Philipp , Götz Michael , Muschelli John , Wick Antje , Neuberger Ulf , Shinohara Russell T. , Sill Martin , Nowosielski Martha , Schlemmer Heinz-Peter , Radbruch Alexander , Wick Wolfgang , Bendszus Martin , Maier-Hein Klaus H. , Bonekamp David
Published: April 2023

S1. Patients epidemiological and clinical characteristics S2. Image intensity normalization S3. Schematic of the three dimensional wavelet decompositions applied to each image sequence. S4. Radiomics features S5. List of radiomic features associated with treatment outcome identified using supervised principal component analysis S6. Supplementary statistical analysis S7. Post-progression therapy after bevacizumab failure
Figure S7 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

Inhibitory effects of miR-644a on the protein expression of PITX2-AKT- GSK-3β-β-catenin axis in vivo. Upper panel, representative images showing the protein expressions of PITX2, P-AKT, P-GSK-3β and active β-catenin examined by IHC in xenograf tissues from miR-644a-overexpressing ESCC and control cells. Lower panel, the IHC scores of PITX2, P-AKT, P-GSK-3β and active β-catenin were significantly lower in xenograft tissues from miR-644a-overexpressing ESCC cells compared to that of control ESCC cells. **P<0.01, *P<0.05.